Information Provided By:
Fly News Breaks for May 23, 2019
ALXN
May 23, 2019 | 06:50 EDT
As previously reported, Wedbush analyst Laura Chico started Alexion with an Outperform rating and $173 price target, saying its launch of Utomiris "marks a new chapter" in the company's history amid its "conversion process" away from the flagship therapy Soliris. The analyst further contends that Ultomiris "raises the competitive bar" to offset the competition threat for Soliris, noting that the company's rich pipeline of 14 different programs and the attractive valuation add to her positive outlook on Alexion shares.
News For ALXN From the Last 2 Days
There are no results for your query ALXN